SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.

Solstice Minerals Limited ( ($AU:SLS) ) just unveiled an announcement. Solstice Minerals Limited has scheduled its 2026 Annual General Meeting for ...

Solstice Minerals Sets Date for 2026 AGM and Director Nominations

Solstice Minerals Limited ( ($AU:SLS) ) has shared an announcement. Solstice Minerals Limited has detailed its 2026 corporate governance framework,...

Solstice Minerals outlines 2026 corporate governance framework and board roles

Solstice Minerals Limited ( ($AU:SLS) ) has shared an announcement. Solstice Minerals Limited has released its annual report for the year ended 30 ...

Solstice Minerals Releases Comprehensive 2026 Annual Report

RBC Capital analyst Sam Crittenden maintained a Buy rating on Solaris Resources on September 15 and set a price target of C$20.00. The company’s sh...

RBC Capital Remains a Buy on Solaris Resources (SLSR)

Solstice Minerals Limited ( ($AU:SLS) ) has provided an announcement. Solstice Minerals Limited has applied for the quotation of 500,000 new ordina...

Solstice Minerals Seeks ASX Quotation for Additional Shares

An update from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals has issued 500,000 fully paid ordinary shares as conside...

Solstice Minerals Issues Shares for Yundamindra Ground Acquisition

Bell Potter analyst Todd Lewis maintained a Buy rating on Solstice Minerals Limited yesterday and set a price target of A$3.25. Lewis covers the Ba...

Bell Potter Reaffirms Their Buy Rating on Solstice Minerals Limited (SLS)

An update from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals has reported outstanding deep diamond drilling results f...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$11.61	-3.09%	4.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$11.61	-3.1%	4.44M
3
4
5
6

SLS

Get SELLAS Life Sciences Group, Inc. Data in Excel

Get SELLAS Life Sciences Group, Inc. Data in Excel